Skip to main content

Brandi Tranae’ Johnson-Weaver

Assistant Professor in Pathology
Pathology
Box 3712, 346 Davison Building, Durham, NC 27710
40 Medicine Circle, 346 Davison Building, Durham, NC 27710

Overview


Vaccines, as invaluable public health tools, modulate host immune responses to induce prophylactic protection against infectious diseases and also serve as potential therapeutics to treat established diseases, such as food allergies. My research aims to identify environmental exposures that modulate host responses to harmful insults, including pathogens, allergens, and drug abuse while utilizing vaccination to regulate immunity to protect the host from harm. One goal of my research is to identify innovative vaccine strategies that incorporate novel adjuvants and formulations to induce protective immunity against several diseases when applied to a mucosal surface. Our laboratory also focuses on identifying host immune responses that correlate with protection against several diseases, including peanut allergies and opioid use disorder, and developing novel adjuvanted vaccine formulations that enhance the magnitude, durability, and efficacy of protective immunity. We also investigate the contribution of environmental factors on host immune responses that regulate susceptibility to allergen sensitization and response to vaccination. Understanding how or why a particular immune response is induced in a host may lead to developing targeted treatment options that are safer and more effective than current therapies.

Current Duke Appointments & Affiliations


Assistant Professor in Pathology · 2025 - Present Pathology, Clinical Science Departments

Recent Scholarly Works


Hapten-conjugated polymeric nanocarriers produced by Flash NanoPrecipitation induce small molecule-specific antibodies in vivo

Journal article Rsc Pharmaceutics · September 1, 2026 Vaccines that induce antibodies specific against small molecules are desirable for a range of applications, including as a tool against the opioid epidemic. Many small molecules are not immunogenic due to their low molecular weight, but can be conjugated t ... Full text Cite

Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection.

Journal article RSC Pharm · July 21, 2026 Mast cells (MC) are innate immune cells that are predominantly localized under the skin and at mucosal surfaces, and play a role in numerous physiological processes, including host response to pathogens. Recently, mast cell activators (MCA) have been ident ... Full text Link to item Cite

Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.

Journal article Clin Exp Vaccine Res · July 2025 PURPOSE: Mast cell activating adjuvants induce vaccine-specific systemic and mucosal immunity when administered intranasally. Bordetella pertussis infects the respiratory tract and caused 0.45% childhood mortality in the United States before implementing p ... Full text Link to item Cite
View All Scholarly Works

Recent Grants


Adjuvant Change Order Option CpG55.2 Expansion Studies

ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2026 - 2028

Bacteriophage virus-like particle vaccines for fentanyl and heroin overdose

ResearchPrincipal Investigator · Awarded by University of New Mexico · 2021 - 2028

Adjuvant Data Integration/Computational Modeling Option

ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2026 - 2027

View All Grants

Education


Duke University, School of Medicine · 2015 Ph.D.